Abbott Laboratories ABT
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, Abbott Laboratories gets an algorithmic score of 41/100. It trades at 100.95 $, with a bearish technical trend (RSI 35.2) and 26.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low beta (0.19): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 32.67 |
| Forward P/E | 16.64 |
| PEG | 1.90 |
| P/B | 3.42 |
| EV/EBITDA | 17.33 |
| P/S | 3.77 |
| ROE % | 10.58 |
| ROA % | 5.33 |
| Gross margin % | 56.85 |
| Operating margin % | 14.71 |
| Net margin % | 11.65 |
| Revenue growth % (y/y) | 13.00 |
| Earnings growth % (y/y) | -47.50 |
| Revenue CAGR % | 0.51 |
| Earnings CAGR % | -2.01 |
| Debt/Equity % | 63.21 |
| Current ratio | 1.38 |
| FCF yield % | 4.21 |
| Dividend yield % | 2.50 |
| Payout % | 78.96 |
Returns
| 1 month | -10.2 % |
| 3 months | +12.1 % |
| 6 months | +0.4 % |
| YTD | -17.2 % |
| 1 year | -22.7 % |
| 3 years | +9.5 % |
| 5 years | -11.1 % |
Risk
| 1-year volatility | 26.8 % |
| Beta | 0.19 |
| 5-year max drawdown | -39.6 % |
| Sharpe 1A | -0.97 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.